These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 33731335)

  • 1. Fibroblast growth factor receptor (
    Al-Obaidy KI; Cheng L
    J Clin Pathol; 2021 Aug; 74(8):491-495. PubMed ID: 33731335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR alterations in urothelial carcinoma: Picking the right target.
    Hubert P; Selmani Z; Loriot Y; Thiery-Vuillemin A
    Bull Cancer; 2021 Jun; 108(6):566-570. PubMed ID: 34020787
    [No Abstract]   [Full Text] [Related]  

  • 3. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
    Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class.
    Weaver A; Bossaer JB
    J Oncol Pharm Pract; 2021 Apr; 27(3):702-710. PubMed ID: 33375902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erdafitinib to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2019 Aug; 55(8):495-501. PubMed ID: 31461086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor receptors across urothelial carcinoma landscape.
    Ertl IE; Shariat SF; Mostafaei H; Ilijazi D; Loriot Y
    Curr Opin Urol; 2020 Jul; 30(4):557-565. PubMed ID: 32452999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.
    Wang S; Burgess M; Major C; English A; Sweeney M; Hartmann A
    J Pathol Clin Res; 2020 Jul; 6(3):207-214. PubMed ID: 32304281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.
    Roubal K; Myint ZW; Kolesar JM
    Am J Health Syst Pharm; 2020 Feb; 77(5):346-351. PubMed ID: 32073123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
    Weickhardt AJ; Lau DK; Hodgson-Garms M; Lavis A; Jenkins LJ; Vukelic N; Ioannidis P; Luk IY; Mariadason JM
    BMC Cancer; 2022 May; 22(1):478. PubMed ID: 35501832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
    Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erdafitinib: First Global Approval.
    Markham A
    Drugs; 2019 Jun; 79(9):1017-1021. PubMed ID: 31161538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.
    Foth M; Ahmad I; van Rhijn BW; van der Kwast T; Bergman AM; King L; Ridgway R; Leung HY; Fraser S; Sansom OJ; Iwata T
    J Pathol; 2014 Jun; 233(2):148-58. PubMed ID: 24519156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.
    D'Angelo A; Bagby S; Galli IC; Bortoletti C; Roviello G
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1139-1146. PubMed ID: 32935605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib.
    de Almeida Carvalho LM; de Oliveira Sapori Avelar S; Haslam A; Gill J; Prasad V
    JAMA Netw Open; 2019 Nov; 2(11):e1916091. PubMed ID: 31755953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
    Aggarwal C; Redman MW; Lara PN; Borghaei H; Hoffman P; Bradley JD; Newman AJ; Feldman MJ; Minichiello K; Miao J; Mack PC; Papadimitrakopoulou VA; Herbst RS; Kelly K; Gandara DR
    J Thorac Oncol; 2019 Oct; 14(10):1847-1852. PubMed ID: 31195180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complexity of FGFR signalling in metastatic urothelial cancer.
    Rodriguez-Vida A; Saggese M; Hughes S; Rudman S; Chowdhury S; Smith NR; Lawrence P; Rooney C; Dougherty B; Landers D; Kilgour E; Arkenau HT
    J Hematol Oncol; 2015 Oct; 8():119. PubMed ID: 26497743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
    Iyer G; Milowsky MI
    Urol Oncol; 2013 Apr; 31(3):303-11. PubMed ID: 22285006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia.
    Hudkins RL; Allen E; Balcer A; Hoffman ID; Iyer S; Neal M; Nelson KJ; Rideout M; Ye Q; Starrett JH; Patel P; Harris T; Swanson RV; Bensen DC
    J Med Chem; 2024 Sep; 67(18):16737-16756. PubMed ID: 39258897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma.
    Zengin ZB; Chehrazi-Raffle A; Salgia NJ; Muddasani R; Ali S; Meza L; Pal SK
    Urol Oncol; 2022 Feb; 40(2):25-36. PubMed ID: 34840077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erdafitinib for the treatment of metastatic bladder cancer.
    Montazeri K; Bellmunt J
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.